JP2021500855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500855A5 JP2021500855A5 JP2020513914A JP2020513914A JP2021500855A5 JP 2021500855 A5 JP2021500855 A5 JP 2021500855A5 JP 2020513914 A JP2020513914 A JP 2020513914A JP 2020513914 A JP2020513914 A JP 2020513914A JP 2021500855 A5 JP2021500855 A5 JP 2021500855A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- mhc class
- terminal
- tmapp
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 313
- 229920001184 polypeptide Polymers 0.000 claims description 301
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 301
- 102000043131 MHC class II family Human genes 0.000 claims description 127
- 108091054438 MHC class II family Proteins 0.000 claims description 127
- 210000004899 c-terminal region Anatomy 0.000 claims description 43
- 230000002519 immonomodulatory effect Effects 0.000 claims description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 33
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 23
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 15
- 239000000427 antigen Substances 0.000 claims description 14
- 108091007433 antigens Proteins 0.000 claims description 14
- 102000036639 antigens Human genes 0.000 claims description 14
- 108091008874 T cell receptors Proteins 0.000 claims description 12
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 235000001014 amino acid Nutrition 0.000 claims 12
- 102000000588 Interleukin-2 Human genes 0.000 claims 6
- 108010002350 Interleukin-2 Proteins 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims 5
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 5
- 108010076181 Proinsulin Proteins 0.000 claims 3
- 108700028369 Alleles Proteins 0.000 claims 2
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 2
- 102000015212 Fas Ligand Protein Human genes 0.000 claims 2
- 108010039471 Fas Ligand Protein Proteins 0.000 claims 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 238000012575 bio-layer interferometry Methods 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101001100327 Homo sapiens RNA-binding protein 45 Proteins 0.000 claims 1
- 102100038823 RNA-binding protein 45 Human genes 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024023312A JP2024063050A (ja) | 2017-09-07 | 2024-02-20 | 抗原提示ポリペプチドおよびその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762555526P | 2017-09-07 | 2017-09-07 | |
| US62/555,526 | 2017-09-07 | ||
| US201862692314P | 2018-06-29 | 2018-06-29 | |
| US62/692,314 | 2018-06-29 | ||
| PCT/US2018/049760 WO2019051094A1 (en) | 2017-09-07 | 2018-09-06 | ANTIGEN PRESENTATION POLYPEPTIDES AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024023312A Division JP2024063050A (ja) | 2017-09-07 | 2024-02-20 | 抗原提示ポリペプチドおよびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500855A JP2021500855A (ja) | 2021-01-14 |
| JP2021500855A5 true JP2021500855A5 (enExample) | 2021-10-14 |
Family
ID=65634574
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020513914A Pending JP2021500855A (ja) | 2017-09-07 | 2018-09-06 | 抗原提示ポリペプチドおよびその使用方法 |
| JP2024023312A Pending JP2024063050A (ja) | 2017-09-07 | 2024-02-20 | 抗原提示ポリペプチドおよびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024023312A Pending JP2024063050A (ja) | 2017-09-07 | 2024-02-20 | 抗原提示ポリペプチドおよびその使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200172595A1 (enExample) |
| EP (1) | EP3678677A4 (enExample) |
| JP (2) | JP2021500855A (enExample) |
| KR (1) | KR20200064083A (enExample) |
| CN (1) | CN111278864A (enExample) |
| AU (1) | AU2018328283A1 (enExample) |
| CA (1) | CA3071881A1 (enExample) |
| IL (1) | IL272332A (enExample) |
| TW (1) | TW201920247A (enExample) |
| WO (1) | WO2019051094A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7071288B2 (ja) * | 2016-05-18 | 2022-05-18 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| MX2019007611A (es) | 2016-12-22 | 2020-07-29 | Cue Biopharma Inc | Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso. |
| CN118453840A (zh) | 2017-03-15 | 2024-08-09 | 库尔生物制药有限公司 | 用于调节免疫应答的方法 |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNOTOLERANCE |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| CA3074839A1 (en) | 2017-09-07 | 2019-03-14 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| WO2020181272A1 (en) * | 2019-03-06 | 2020-09-10 | Cue Biopharma, Inc. | Antigen-presenting polypeptides with chemical conjugation sites and methods of use thereof |
| JP7691927B2 (ja) * | 2019-03-06 | 2025-06-12 | キュー バイオファーマ， インコーポレイテッド | Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 |
| TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向ＭＡｄＣＡＭ之免疫耐受性 |
| TW202128961A (zh) | 2019-11-20 | 2021-08-01 | 美商安維塔生物科學股份有限公司 | 細胞激素融合蛋白及其醫藥組合物及治療應用 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| MX2022011163A (es) * | 2020-03-11 | 2022-10-18 | Ambrx Inc | Conjugados de polipeptidos de interleucina-2 y sus usos. |
| EP4143329A4 (en) | 2020-04-28 | 2024-10-16 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| CN111808170A (zh) * | 2020-06-29 | 2020-10-23 | 江苏为真生物医药技术股份有限公司 | 多肽、hla-dr蛋白及其制备方法和应用 |
| JP2023541366A (ja) * | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
| WO2022056015A1 (en) * | 2020-09-09 | 2022-03-17 | Cue Biopharma, Inc. | Mhc class ii t-cell modulatory multimeric polypeptides and methods of use thereof |
| CA3209361A1 (en) * | 2021-03-19 | 2022-09-22 | Ronald D. Seidel Iii | T-cell modulatory polypeptides and methods of use thereof |
| EP4308143A4 (en) * | 2021-03-19 | 2025-06-04 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| US20240189403A1 (en) * | 2021-04-21 | 2024-06-13 | Cue Biopharma, Inc. | Antigen-Presenting Polypeptides with Chemical Conjugation Sites and Methods of Use Thereof |
| CN117561280A (zh) * | 2021-04-21 | 2024-02-13 | 库尔生物制药有限公司 | 携带TGF-β的抗原呈递多肽复合物及其使用方法 |
| CN117327145A (zh) * | 2022-06-24 | 2024-01-02 | 北京博辉瑞进生物科技有限公司 | 肽、肽修饰的sis膜、其制备方法及应用 |
| EP4587467A2 (en) * | 2022-09-12 | 2025-07-23 | Cue Biopharma, Inc. | Interleukin-2 polypeptides, fusion polypeptides, and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2783699A1 (en) * | 2003-09-05 | 2014-10-01 | Oregon Health & Science University | Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells |
| GB2409456B (en) * | 2003-10-30 | 2006-01-04 | Proimmune Ltd | Oligomeric receptor ligand pair member complexes |
| AU2010206840B2 (en) * | 2009-01-21 | 2015-02-05 | Amgen Inc. | Compositions and methods of treating inflammatory and autoimmune diseases |
| JP6652932B2 (ja) * | 2014-06-18 | 2020-02-26 | アルバート アインシュタイン カレッジ オブ メディシン | ｓｙｎＴａｃポリペプチド及びその使用 |
| ES2979088T3 (es) * | 2015-03-05 | 2024-09-24 | Fred Hutchinson Cancer Center | Proteínas de fusión inmunomoduladoras y usos de las mismas |
| US20190365656A1 (en) * | 2016-01-04 | 2019-12-05 | Cour Pharmaceuticals Development Company, Inc. | Particles encapsulating fusion proteins containing linked epitopes |
| MX2018008515A (es) * | 2016-01-11 | 2019-05-09 | Rubius Therapeutics Inc | Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias. |
| US20190062400A1 (en) * | 2016-03-02 | 2019-02-28 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
| CN109071623B (zh) * | 2016-05-04 | 2022-05-27 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
-
2018
- 2018-09-06 AU AU2018328283A patent/AU2018328283A1/en not_active Abandoned
- 2018-09-06 KR KR1020207009763A patent/KR20200064083A/ko not_active Ceased
- 2018-09-06 CA CA3071881A patent/CA3071881A1/en active Pending
- 2018-09-06 EP EP18854499.3A patent/EP3678677A4/en active Pending
- 2018-09-06 WO PCT/US2018/049760 patent/WO2019051094A1/en not_active Ceased
- 2018-09-06 CN CN201880068747.7A patent/CN111278864A/zh active Pending
- 2018-09-06 JP JP2020513914A patent/JP2021500855A/ja active Pending
- 2018-09-06 TW TW107131331A patent/TW201920247A/zh unknown
-
2020
- 2020-01-29 IL IL272332A patent/IL272332A/en unknown
- 2020-02-12 US US16/789,057 patent/US20200172595A1/en not_active Abandoned
-
2023
- 2023-01-31 US US18/103,809 patent/US20240034767A1/en active Pending
-
2024
- 2024-02-20 JP JP2024023312A patent/JP2024063050A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500855A5 (enExample) | ||
| CN111148756B (zh) | T细胞受体 | |
| KR102267345B1 (ko) | Ｔ 세포 수용체 | |
| DK1935427T3 (en) | APPLICATIONS OF SOLUBLE, MUTANT CTLA4 MOLECULES | |
| JP5612623B2 (ja) | 高親和性ｈｉｖｔ細胞レセプター | |
| JP2020511949A5 (enExample) | ||
| JP2020533273A5 (enExample) | ||
| JP2017519491A5 (enExample) | ||
| JP7682927B2 (ja) | 特異的結合性分子 | |
| JP2017527272A5 (enExample) | ||
| IL272085B (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| JP2019512222A5 (enExample) | ||
| JP2021522835A (ja) | 二機能性結合ポリペプチド | |
| JP2019522466A5 (enExample) | ||
| AU2016375994A1 (en) | T cell receptors specific for the NY-ESO-1 tumor antigen-HLA-A*02 complex | |
| JP2019522465A5 (enExample) | ||
| CN106414482A (zh) | T细胞受体 | |
| JP7742354B2 (ja) | Ｇ１２ｖ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体 | |
| JP7313017B2 (ja) | ＭＨＣクラスＩａオープンコンフォーマー | |
| JP2024517884A (ja) | ｐ５３におけるＣ１３５Ｙ、Ｒ１７５Ｈ又はＭ２３７Ｉ変異を認識するＴ細胞受容体 | |
| JPWO2020243315A5 (enExample) | ||
| WO2022008418A1 (en) | Specific binding molecules | |
| JPWO2020257191A5 (enExample) | ||
| JPWO2020180501A5 (enExample) | ||
| JPWO2020132297A5 (enExample) |